Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 60/100

Failure Rate

26.3%

5 terminated/withdrawn out of 19 trials

Success Rate

66.7%

-19.8% vs industry average

Late-Stage Pipeline

16%

3 trials in Phase 3/4

Results Transparency

80%

8 of 10 completed trials have results

Key Signals

2 recruiting8 with results

Enrollment Performance

Analytics

Phase 1

10(52.6%)

Phase 2

5(26.3%)

Phase 3

2(10.5%)

Phase 4

1(5.3%)

N/A

1(5.3%)

19Total

Phase 1(10)

Phase 2(5)

Phase 3(2)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (19)

Showing 19 of 19 trials

NCT06996652Phase 2Not Yet Recruiting

An Exploratory Study of the Potential for Rational Immune System Manipulation to Prevent Emergence of Synucleinopathy Manifestations in Persons With REM Sleep Behavior Disorder (RBD)

Role: collaborator

NCT06870812Not ApplicableRecruiting

Rapid Evacuation and Access of Cerebral Hemorrhage Trial

Role: collaborator

NCT05743946Phase 4Completed

Trikafta for Patients With Non-cystic Fibrosis Bronchiectasis

Role: collaborator

NCT06464588Phase 1Recruiting

A Phase 1 Open-Label Study of the Safety of Intravenous Allogeneic Neonatal Mesenchymal Cells (nMSCs) in Young Adult (1A) and Pediatric (1B) Patients With Dilated Cardiomyopathy (DCM)

Role: collaborator

NCT05035862Phase 1Terminated

Mechanisms of Interferon Gamma-primed Mesenchymal Stromal Cells (MSCs) for Moderate-to-severe Persistent Asthma

Role: collaborator

NCT04294290Phase 1Completed

Open Label Phase I hCT-MSC in Toddlers With Autism Spectrum Disorder

Role: collaborator

NCT05501548Phase 2Terminated

Phase II Study of PARP Inhibitor Olaparib and IV Ascorbate in Castration Resistant Prostate Cancer

Role: collaborator

NCT04484077Phase 1Completed

hCT-MSC Infusion in Adults With Autism Spectrum Disorder